In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors

Yuan Ding¹,*, Wei Cui²,*, Dan Sun¹, Gui-Ling Wang¹, Yu He¹, Shuai Meng¹, Jian-Hua Chen³, Ying Xie¹, Zhi-Qiang Wang⁴

¹Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, ²School of Pharmacy, School of Pharmaceutical Sciences, Peking University, ³School of Chemistry and Chemical Engineering, University of Chinese Academy of Sciences, Beijing, ⁴School of Medicine, Jianghan University, Wuhan, People’s Republic of China; *Department of Chemistry and Biochemistry, Kent State University, Geauga, Burton, OH, USA

*These authors contributed equally to this work

Abstract: In vivo evaluation of drug delivery vectors is essential for clinical translation. In BALB/c nude mice bearing human breast cancer tumors, we investigated the biocompatibility, pharmacokinetics, and pharmacodynamics of doxorubicin (DOX)-loaded novel cell-penetrating peptide (CPP)-modified pH-sensitive liposomes (CPPL) (referred to as CPPL(DOX)) with an optimal CPP density of 4%. In CPPL, a polyethylene glycol (PEG) derivative formed by conjugating PEG with stearate via acid-degradable hydrazone bond (PEG2000-Hz-stearate) was inserted into the surface of liposomes, and CPP was directly attached to liposome surfaces via coupling with stearate to simultaneously achieve long circulation time in blood and improve the selectivity and efficacy of CPP for tumor targeting. Compared to PEGylated liposomes, CPPL enhanced DOX accumulation in tumors up to 1.9-fold (p<0.01) and resulted in more cell apoptosis as a result of DNA disruption as well as a relatively lower tumor growth ratio (T/C%). Histological examination did not show any signs of necrosis or inflammation in normal tissues, but large cell dissolving areas were found in tumors following the treatment of animals with CPPL(DOX). Our findings provide important and detailed information regarding the distribution of CPPL(DOX) in vivo and reveal their abilities of tumor penetration and potential for the treatment of breast cancer.

Keywords: tumor targeting, TUNEL stain, hemolysis, therapy for breast cancer, pharmacokinetics

Abbreviations
AUC, area under the concentration–time curve; BBB, blood–brain barrier; BMCs, bone marrow cells; CCL, CPP-modified conventional liposomes; CL, conventional liposomes; CCL(DOX), doxorubicin-loaded CPP-modified conventional liposomes; CL(DOX), doxorubicin-loaded conventional liposomes; CPP, cell-penetrating peptide; CPPL, CPP-modified pH-sensitive PEGylated liposomes; CPPL(DOX), doxorubicin-loaded CPP-modified pH-sensitive PEGylated liposomes; DAU, daunomycin; DOX, doxorubicin; DSPE-PEG2000, poly(ethylene glycol)-N-distearoyl-phosphatidylethanolamine; EDCI, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; EPR, enhanced permeability and retention; H&E, hematoxylin and eosin; HPLC, high-pressure liquid chromatography; NS, normal saline; PDI, polydispersity index; PEG, polyethylene glycol; PHS, mPEG2000-hydrazone-stearate (mPEG2000-Hz-stearate); PL, PEGylated liposomes; PL(DOX), doxorubicin-loaded PEGylated...
liposomes; RBCs, red blood cells; RV, relative tumor volume; SD, standard deviation; SPC, soybean phosphatidylcholine; SRB, sulfurhodamine B; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling.

**Introduction**

The health burden of cancer is increasing worldwide, and breast cancer has become the second leading cancer-related cause of death in women. Common chemotherapeutics invariably disrupt normal tissues, which leads to irreversible toxic and adverse effects. Currently, nanomedicines such as liposomal formulation have become a successful drug delivery system in clinics for their capabilities of altering the behaviors of chemotherapeutics in vivo and reducing their toxicity on normal tissues.

DOX hydrochloride liposome injection\(^1\) (Doxil\(^\Reg\), Lipodox\(^\Reg\), or Caelyx\(^\Reg\)) was approved in 1995 by the FDA as the first antitumor liposome preparation. With the presence of PEG on the surface of the liposomes, DOX hydrochloride liposome injection, named here as PL(DOX), has the ability to passively accumulate in tumor tissues through EPR effects\(^4\) and prolong the circulation time of DOX in blood. However, PEGylation reduces the extent of interactions of liposomes with target cells, resulting in improper cellular uptake as well as poor endosomal escape, a factor that ultimately leads to a significant loss of the pharmacological effect of a drug.\(^5,6\)

At present, intracellular or organelle-specific targeting is becoming an emerging concept for improving nanomedicine actions. CPPs,\(^7,8\) small molecular transporters with the capabilities of cell penetration, internalization, and endosomal escape, due to the presence of large number of positively charged arginine residues in acidic environment, have the potential to be useful in drug delivery system.\(^10,11\) However, poor specificity for cells is one of the drawbacks of CPPs.\(^12\) By utilizing the function of hydration shell of PEG and acid sensitivity of hydrazone bond, we synthesized a kind of CPPL\(^13\) to improve the selectivity of these peptides for tumor targeting. In CPPL, CPP was directly attached to liposome surfaces via coupling with stearate to avoid the hindrance of PEG as a linker on the penetrating efficiency of CPP, and a PEG derivative was synthesized by conjugating PEG with stearate via acid-degradable hydrazone bond (PHS) and was incorporated into the lipid membrane. In vitro studies including HPLC, flow cytometry, ex vivo imaging, and confocal laser-scanning microscopy indicated that 8 mol% PHS was enough to cover 4 mol% CPPL at neutral pH and that CPPL was too stable to be captured by normal tissues which consequently led to a long circulation time in blood.\(^13\)

When CPPL arrived at tumor cells, PEG on PHS was completely cleaved from liposome surface to expose CPP sufficiently under acidic environments in tumor for its penetration across tumor cells and helping entrapped cargoes such as DOX escape from lysosomes and gaining more opportunities to enter nucleus to exert pharmacological effects.\(^13\) CPPL not only balanced the interplay between cell binding and blood circulation of PL but also promised higher efficiency of CPP in internalizing the liposomes into targeted subcellular compartments.\(^13\)

However, the presence of high serum concentrations and nonspecific binding to extracellular components can interfere with the in vivo performance of the delivery vector. In this study, we further explored the pharmacokinetics and pharmacodynamics of CPPL(DOX) in BALB/c nude mice bearing human breast tumors. PL were chosen as a comparative delivery vector. Preclinical in vitro and in vivo studies of CPPL for DOX loading, including formulation, mechanism of tumor cell uptake, pharmacokinetics, biodistribution, pharmacodynamics, and biocompatibility, proved the potential of CPPL and provided the basis for entering clinical trials due to the non-immunogenicity of CPP and the stable quality of PHS which recommends their use in future CPPL manufacturing.

**Materials and methods**

**Materials**

SPC (99% purity) was purchased from Shanghai Taiwei Chemical Company (Shanghai, People’s Republic of China). Cholesterol was purchased from Alfa Aesar Co., Ltd. (Ward Hill, MA, USA). Stearate was obtained from Beijing Chemical Factory (Beijing, People’s Republic of China). EDCI was obtained from J&K Scientific, Ltd. (Beijing, People’s Republic of China). CPPs (GGRRRRRRRRR-amide) were provided by KTG Pharmaceuticals, Inc. (Wuhan, People’s Republic of China). DSPE-PEG2000 was purchased from Shanghai Advanced Vehicle Technology Pharmaceutical, Ltd. (Shanghai, People’s Republic of China). PHS was synthesized and characterized in our laboratory.\(^13\)

**Cell cultures**

The MCF-7 human breast cancer cell line was purchased from the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (Beijing, People’s Republic of China). The cells were cultured in RPMI 1640 containing 2 mM L-glutamine and were supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. Cultures were maintained at 37°C
in a humidified 5% CO₂ incubator. The cells were subcultured approximately every 3 days throughout the experiments.

Animals

BALB/c nude mice (female, 20±2 g) were provided by the Animal Center of Peking University Health Science Center. Animals were housed at 25°C and 55% humidity under natural light with free access to food and water. All animal-related experiments were performed in full compliance with institutional guidelines and approved by the Institutional Authority for Laboratory Animal Care of Peking University (No LA2016155).

Establishment of BALB/c nude mice bearing MCF-7 model

Breast tumors were grown in BALB/c nude mice by subcutaneous injections of 200 μL of MCF-7 suspension (1x10⁷ cells/mL) in PBS into the right armpits. At the 7th day after tumor inoculation, the volume of tumor was measured with a vernier caliper and estimated using the formula: volume = length (cm) × width (cm) × 0.5236. After 15 days of human breast tumor implanting, animals with tumor volume > 100 mm³ were chosen for pharmacokinetic and pharmacodynamic studies.

Preparation of CPPL(DOX) and PL(DOX)

DOX was loaded into CPPL by a combination of the pH gradient¹⁶ and post-reaction methods¹³,¹⁷ as shown in Figure 1A. In brief, dried lipid films composed of SPC, cholesterol, and stearate at a molar ratio of 100:50:4 were hydrated with 300 mmol/L citrate buffer (pH 4.0) to prepare CL with a final lipid concentration of 1 mmol/L. After sonication for 10 min at 25°C, an aliquot of sodium carbonate solution (0.5 mmol/L) was added to the suspensions to create an external liposome medium of pH 7.8 and internal liposome medium of pH 4.0. To load DOX into liposomes, a mixture of the liposomal suspension and DOX at 100:8 molar ratio (lipid:drug) was incubated at 55°C–60°C for 30 min, cooled to room temperature in the dark, flushed with N₂, and stored in the refrigerator overnight. Afterward, CPP was conjugated with CL via an activated stearate group. During the process, EDCI was first added into the CL(DOX) containing stearate, and the mixture was stirred for 1 min. S-NHS was then added at a stearate/EDCI/S-NHS molar ratio of 1:40:100. After stirring the mixture for 15 min, the pH was adjusted to 12. As the coupling efficiency of CPP with stearate was 75%, CPP was reacted with NHS-activated stearate group on CL at the molar ratio of 4:3 to form CCL for DOX loading. To obtain 4% CPPL for DOX loading, 8 mol% PHS of SPC was incubated with CCL at pH 7.0 for 12 h, and suspensions in ultrafilter tubes (MWCO, 30,000 Da) were centrifuged at 1,000×g for 30 min to remove unreacted EDCI, S-NHS, and CPP.

DOX encapsulated into PL(DOX) served as the control, which was prepared using pH gradient method (Figure 1A). In brief, SPC/Chol/DSPE-PEG2000 (100:50:8 mol/mol/mol) was dissolved with medium containing chloroform and methanol at a volume ratio of 4:1 in a round-bottom flask. The solvent was evaporated at 37°C on a rotary evaporator until homogeneous lipid films formed on the glass wall. DOX was then loaded into PL as described.

Characterization of CPPL(DOX) and PL(DOX)

CPPL(DOX) were diluted with distilled water to analyze the changes in size and zeta potential of liposomes caused by the 4 mol% CPP modification. After filtering each liposome with a 0.45 μm filter membrane, size distribution (nm), PDI, and zeta potential were determined using Nano ZS ZEN3600 Zetasizer (Malvern Instruments, Ltd., Malvern, UK) at 25°C. Assays were performed 15 times with an equilibrium time of 60 s. DOX encapsulation efficiency (ee%) in liposomes was determined by comparing the adsorption density at 485 nm of eluted liposome solutions after removing free drugs through a Sephadex G-50 column with the primary liposome suspensions in an equal volume.

Leakage stability of CPPL(DOX) in vitro

To simulate drug release profiles of CPPL(DOX) in blood and tumor environment in vitro, we chose three kinds of release media including PBS of pH 7.0, PBS of pH 6.0, and PBS of pH 7.0 containing 10% horse serum. In brief, 1.0 mL PL(DOX) and CPPL(DOX) were sealed into dialysis bags (MWCO, 50,000 Da), and incubated in 30 mL of release medium at 37°C in dark, with continuous stirring for 12 h. A 1 mL aliquot was removed at predetermined time points, and replaced with 1 mL of fresh medium. The released DOX concentrations ([c]sample, μg/mL) were determined with a Cary Eclipse spectrofluorometer (Varian Corporation, Palo Alto, CA, USA) at excitation and emission wavelengths of 437 and 584 nm, respectively. The cumulative release proportion and the proportion of total DOX released from liposomes were calculated and plotted at given time points.

Evaluation of hemolytic activity

Hemolysis studies were performed to evaluate the safety of liposomes for in vivo applications. Rat RBCs were harvested...
by centrifugation at 1,000×g for 10 min following the collection of rat blood in EDTA-containing tubes. The plasma supernatant was discarded, and PBS was added to wash the RBC three times. The RBCs were resuspended in PBS to a concentration of 4×10^6 cells/mL. PL(DOX) and CPPL(DOX) were diluted with PBS at a phospholipid concentration of 50, 100, 200, 400, 600, and 800 μmol/L. An equal volume of liposomes and RBCs was incubated for 1 h in a water
bath at 37°C followed by centrifugation at 1,000×g for 10 min. Absorbance of hemoglobin in the supernatant solution was measured at 570 nm using an ELISA Reader (Thermo Fisher Scientific, Waltham, MA, USA). RBC hemolysates in PBS solutions and in 1% Triton X-100 were used as negative and positive controls, respectively. The percent of hemolysis was calculated with the formula: percent hemolysis = (A[liposomes] – A[PBS])/A(Triton-100)×100%. The sample with less than 10% hemolysis was considered nontoxic.

In vitro cytotoxicity of CPPL(DOX)

In vitro cell viability was determined with MCF-7 cells using SRB stain method. Cells were seeded in a 96-well plate (1×10^4 cells/well) and incubated for 24 h at 37°C with 5% CO₂. Cells were then washed with 100 μL/well PBS and incubated with dilutions of DOX, CPPL(DOX), CCL(DOX), and PL(DOX) at pH 6.0. Equivalent DOX concentrations (2.5, 5.0, 10, 20, 40, 60, and 80 μg/mL) of each formulation were prepared by diluting with fresh serum-free RPMI 1640. Cell viability was measured via an SRB assay after an additional 24 h incubation at 37°C. Serum-free RPMI 1640 and 1% Triton X-100 culture solutions were used as negative and positive controls, respectively. Drug-administered cells were rinsed five times with deionized water, dried at 37°C after rinsing with ice-cold PBS, and fixed with 10% trichloroacetic acid at 4°C for 1 h. Then, 100 μL of 0.4% SRB in 1% aceticum was added to each well at room temperature and incubated for 30 min to prepare for staining. Each well was then dried at the same temperature after rinsing five times again with 1% acetum. SRB in cells was dissolved with 200 μL of 10 mM Tris solution and shook at 37°C for 30 min. The optical density at 540 nm was recorded using Flexstation® 3 (Molecular Devices, Sunnyvale, CA, USA). Cytotoxicity was expressed as the percentage of the control. The IC₅₀ was calculated using SPSS software (version 16.0; SPSS Inc., Chicago, IL, USA).

Pharmacokinetics and bio-distribution of CPPL(DOX) in nude mice bearing tumor

Thirty-six breast tumor-bearing BALB/c female nude mice were randomly divided into two groups. CPPL(DOX) and PL(DOX) were administered a dose of 5 mg DOX/kg via the tail vein. Subsequently, blood samples (0.5 mL) were collected into heparin-containing tubes at 30 min and 1, 2, 4, and 8 h from each animal. Plasma was extracted by centrifugation at 2,000×g for 10 min and stored at −20°C. Forty microliters of DAU (400 μg/mL) was used as an internal standard and added to 500 μL of plasma, and the drug was extracted using organic solvent (chloroform:methyl alcohol, 4:1, v/v) by centrifugation at 4,500×g for 15 min. The supernatant was dried with N₂ gas and reconstituted with mobile phase before being measured using HPLC with the fluorescent detector at λex =437 nm and λem =584 nm (Agilent 1100 series combined with Agilent technologies 1260 infinity Detector; Kromasil C18-ODS 250×4.6 mm, 5 μm column; Dikma Co., Ltd, Lake Forest, CA, USA; mobile phase, 70% CH₃OH:30% H₂O; flow rate, 1.0 mL/min, injection volume, 20 μL). Pharmacokinetic parameters such as t₁/₂, AUC, volume of distribution, and clearance were calculated by fitting the concentrations of DOX to a noncompartmental model using DAS version 2.1.

In the bio-distribution study at time points of 30 min and 1, 2, 4, and 8 h, three tumor-bearing mice per group were sacrificed to obtain blood, major organs (the heart, liver, spleen, lung, and kidney), and tumors. Tissues were immediately washed twice with NS (0.9% NaCl), wiped with filter paper, weighed, and homogenized with citric acid buffer (pH 6.8). The internal standard substance DAU (100 μL, 400 μg/mL) was added to 2 mL of each homogenate, and samples were processed as described and detected using HPLC.

Therapy for breast tumor

Fifteen breast tumor-bearing BALB/c female nude mice were randomly divided into three groups (n=5 per group), and this was designated as day 0. From day 1, mice were treated with CPPL(DOX) and PL(DOX) via tail vein injection at a dose of 2.5 mg DOX/kg. NS served as control. Administration was done every other day for a total of four doses per mouse. Mice were weighted, and tumor sizes were monitored every day for 9 days. RV of each group was calculated with the formula: RV = V / V₀ where V is the tumor volume at the monitoring time point during the experimental period and V₀ is the original tumor volume prior to the first treatment. The relative tumor growth ratio was calculated with the formula: T/C% = (T / C) ×100%, where T / C is the RV after treating with drug and C / V₀ is the RV after treating with NS as control. A T/C% of 40% indicated an effective treatment.

H&E and TUNEL stain

On day 9, mice were sacrificed, and the tumor samples were used for H&E staining and TUNEL analysis. Tumor samples were fixed in 4% paraformaldehyde and embedded in paraffin. The sections were stained with Harris hematoxylin solution, washed in running tap water, and differentiated in 1% acid alcohol for 10 s. The stained tissue sections were then rinsed in tap water and stained

Dovepress

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 18-Apr-2019
For personal use only.
with 1.36% lithium carbonate solution. The slides were then dehydrated in 95% alcohol and counterstained with eosin Y-phloxine B solution for 5–10 s. The stained tissue sections were cleared in xylene, mounted with Cytoseal 60 (Sigma), and observed under a light microscope.

For specific TUNEL staining, tissue samples of MCF-7 tumors were frozen in optimal cutting temperature embedding medium, cut into 4-μm-thick sections, and fixed in 4% (v/v) paraformaldehyde for 15 min at room temperature. The sectioned samples were washed three times with PBS and incubated with 1% (v/v) Triton X-100 (Sigma Co.) for 5 min on ice. The TUNEL reaction mixture was then added to the tissue sections, which was then incubated in the dark under humidified atmosphere at 37°C for 1 h. The samples were washed three times with PBS and treated with Hoechst 33258 (Molecular Probes Inc., Eugene, OR, USA) for 15 min prior to microscopic analysis using a confocal laser scanning microscope (TCS SP5; Leica, Heidelberg, Germany).

**Biocompatibility of CPPL(DOX)**

The in vivo biocompatibility of liposomes was evaluated by histological examination of tissue sections from normal mice. CPPL(DOX), PL(DOX), and DOX were intravenously administered to normal BALB/c mice at a dose of 2.5 mg DOX/kg every other day with a total of four doses per mouse. On the 9th day of administration, the mice were sacrificed, and the hearts, livers, lungs, and kidneys were separated for BMCs. The BMCs were obtained using centrifugation. The BMCs were observed for ballooning of hepatocytes, enlargement of nuclei or Kupffer cells, and granulomas. Similarly, the splenic tissue was evaluated for necrosis and inflammation. The hearts and lungs were also examined for signs of necrosis and extravasation of RBCs and thickening of alveoli, respectively. Kidneys were observed for inflammation and necrosis.

The myelosuppressive effect was monitored using BMCs. After the mice were euthanized on day 9, a thigh tumor was frozen in optimal cutting temperature embed, and observed under a light microscope.

**Results and discussion**

**Characterization of CPPL(DOX) and PL(DOX)**

CPPL(DOX) and PL(DOX) suspension demonstrated red opalescence. As shown in Table 1, their average sizes were approximately 120 nm with PDI <0.2. Compared with PL(DOX), the zeta potential of CPPL(DOX) significantly changed in a positive direction due to the arginine-rich residues of CPP (p <0.01), which may be beneficial for improving tumor cell penetration and endosomal escape. The ee% of CPPL(DOX) prepared using the post-reaction method was about 90%, which was consistent with the ee% of PL(DOX). The post-reaction method is a preferable preparation technique for loading DOX into CPPL because it avoided the interaction between DOX and CPP in the external medium of liposomes which impeded DOX from entering the internal water phase of liposomes.

**Leakage behavior of CPPL(DOX) in vitro**

The profiles of DOX release from liposomes in vitro are shown in Figure 1B. In the release medium of pH 7.0 PBS containing horse serum, there were no significant differences between CPPL(DOX) and PL(DOX) (p >0.05), indicating that CPPL(DOX) were as stable in blood as PL(DOX). However, when the pH of the release PBS medium decreased to 6.0, the release rate of DOX from CPPL was significantly higher than that of PL. This demonstrated that CPP modification of liposomes promoted DOX leakage caused by DOX and CPP interactions, which included cation–π interaction and the formation of hydrogen bonds when guanidinium group of CPP was parallel to the planar aromatic chromophore of DOX. The lower pH caused more protonation of CPP amino groups, which then led to more DOX release from CPPL. The leakage behavior of CPPL(DOX) showed the advantages of DOX escape from endosomes in an acid microenvironment and stability in neutral blood environment.

**Table 1** Characterization of CPPL(DOX) and PL(DOX) (n=3)

<table>
<thead>
<tr>
<th>Group</th>
<th>ee%</th>
<th>Size (nm)</th>
<th>PDI</th>
<th>Zeta potential (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPPL(DOX)</td>
<td>8.97±3.41</td>
<td>121.25±3.46</td>
<td>0.194±0.009</td>
<td>-9.26±2.75</td>
</tr>
<tr>
<td>PL(DOX)</td>
<td>9.09±1.67</td>
<td>116.65±3.32</td>
<td>0.184±0.015</td>
<td>-21.6±2.06</td>
</tr>
</tbody>
</table>

Abbreviations: CPPL(DOX), doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive PEGylated liposomes; PL(DOX), doxorubicin-loaded PEGylated liposomes; PDI, polydispersity index.
Evaluation of hemolytic activity

CPP normally exhibits toxicity because of its cell penetrating and nonselective properties. Based on a single hemolysis experiment, although there was a little significant difference in hemolysis between CPPL(DOX) and PL(DOX) when phospholipid concentrations were <400 μmol/L (Figure 1C), CPPL(DOX) were considered nontoxic due to their low hemolysis (<10%). The dose of DOX hydrochloride liposome injection used for clinical intravenous drip administration is 1.2 mg/kg, the ratio of DOX and phospholipid in formulation is 1:10 (w:w), and the blood volume in adults is about 86 mL/kg. Thus, the phospholipid concentration in the blood is about 186 μmol/L when DOX hydrochloride liposome injection is administrated via intravenous injection, which is far less than the threshold concentration of 400 μmol/L. That is, the hemolysis of CPPL(DOX) is about 5% when they are exposed to tumors via intravenous injection at the dosage of DOX hydrochloride liposome injection available in the market. But in fact, CPPL(DOX) are preferably administrated by intravenous drip, and the hemolytic activity of CPPL(DOX) is too low to be mentioned. These findings suggest that CPPL(DOX) are safe for clinical application.

In vitro cytotoxicity of CPPL(DOX)

The IC\textsubscript{50} calculated from the viability of MCF-7 cells after 24 h incubation with DOX and DOX-loaded liposomes at pH 6.0 (Figure 1D) showed that the cytotoxicity of DOX encapsulated into liposomes was lower than that of free DOX in direct contact with cells. The lower IC\textsubscript{50} values of CPPL(DOX) revealed that CPPL at pH 6.0 significantly promoted the efficacy of DOX, which suggests they are a potential delivery system for anticancer drugs.

These findings were in great agreement with the structure design of CPPL, in which CPP directly attached to liposomal surfaces via coupling with stearate and a PEG derivative PHS formed by conjugating PEG with stearate via an acid-degradable hydrazone bond covered the liposomal surface. We have confirmed that PHS is highly sensitive to the acidic environment. It stabilizes on the surface of liposomes to shield CPP and prevents its penetration into normal cells at pH 7.0. The same IC\textsubscript{50} value as CCL(DOX) (Figure 1D) demonstrated that PHS on CPPL leaves liposomes completely to expose CPP on their surface which is beneficial for promoting penetration and endosomal escape at pH 6.0. Entrapped cargo such as DOX gain more opportunities to enter the nucleus to inhibit DNA synthesis and initiate DNA cleavage by type II topoisomerases.

Pharmacokinetics and bio-distribution of CPPL(DOX) in nude mice bearing tumor

We determined in vivo DOX concentration by HPLC using the internal standard. The resulting chromatograms were essentially free from endogenous artifacts. Representative chromatograms are shown in Figure 2, which includes a blank plasma sample (Figure 2A), a plasma sample (Figure 2B), and a tumor sample (Figure 2C) obtained 30 min after the intravenous injection of 5 mg DOX/kg of CPPL(DOX). The typical retention time for DOX and the internal standard (DAU) was 5.4 min and 9.2 min, respectively, and the peaks were satisfactory and suitable for quantitative analysis.

Recovery of DOX from mouse plasma and tissue samples showed acceptable ratios of DOX to DAU (Table 2). The DOX concentration was \( A_{DOX}/A_{DAU} = 1.3231 \) (μg/mL) +0.0365; \( R^2=0.9999 \). Linearity covered a range of 3.125 ng/mL–4.00 μg/mL, and the lower limits of quantification were 0.625 ng/mL. The intra- and inter-day precisions of 0.0625, 0.5, and 2.0 μg/mL DOX in blank and sample tissues were assessed by calculating the relative SD and were <5% indicating that the method was reliable and reproducible.

After administration of formulation via the tail vein to the nude mice bearing breast tumors, the profile of concentration versus time of the plasma with two formulations was
analyzed using DAS software. The results showed that the pharmacokinetics of the two formulations complied with the two-compartment model. The pharmacokinetic parameters are summarized in Table 3. Compared with PL(DOX), the half-life of CPPL(DOX) did not change significantly, demonstrating that CPPL(DOX) remained in the circulation for a longer period and provided an effective distribution of drugs to tumors. In the bloodstream, CPPL(DOX) were stable at a pH >7.0 because of the stable hydrazone bond in PHS, and CPP was masked completely by the PEG. CPPL constructed in the study overcome the drawbacks of CPP-SSL, we reported before, which was cleared from the blood quickly due to the exposure of CPP on the surface of liposome.

In addition, as shown in Figure 3, DOX plasma concentrations were lower in nude mice bearing tumors that were administered CPPL(DOX) than those administered PL(DOX); this led to higher clearance of CPPL(DOX), lower AUC, and lower mean resident time, which may have been the result of higher distribution in other tissues. The mean concentration–time profile of each tissue for the two formulations is also presented in Figure 3.

Table 2 
Recoveries of DOX from plasma and tissue samples (n=3)

<table>
<thead>
<tr>
<th>c (μg/mL)</th>
<th>Heart</th>
<th>Liver</th>
<th>Spleen</th>
<th>Lung</th>
<th>Kidney</th>
<th>Brain</th>
<th>Tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.125</td>
<td>77.25±10.54</td>
<td>78.16±8.68</td>
<td>88.42±13.47</td>
<td>80.37±8.75</td>
<td>88.15±7.24</td>
<td>83.40±6.47</td>
<td>85.43±2.46</td>
</tr>
<tr>
<td>0.50</td>
<td>86.97±4.53</td>
<td>87.69±10.25</td>
<td>82.50±7.98</td>
<td>84.72±12.14</td>
<td>81.36±9.94</td>
<td>101.74±9.47</td>
<td>89.70±6.97</td>
</tr>
<tr>
<td>2.00</td>
<td>87.14±6.04</td>
<td>78.38±0.21</td>
<td>86.76±6.51</td>
<td>86.82±1.99</td>
<td>83.39±1.73</td>
<td>78.99±7.37</td>
<td>94.12±5.92</td>
</tr>
</tbody>
</table>

Abbreviation: DOX, doxorubicin.

Table 3 
The pharmacokinetic parameters of PL(DOX) and CPPL(DOX) (n=6)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Unit</th>
<th>PL(DOX)</th>
<th>CPPL(DOX)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>mg/mL</td>
<td>2.875±0.277</td>
<td>2.244±0.137</td>
</tr>
<tr>
<td>α</td>
<td>h⁻¹</td>
<td>2.206±0.144</td>
<td>2.075±0.264</td>
</tr>
<tr>
<td>B</td>
<td>mg/mL</td>
<td>0.118±0.006</td>
<td>0.03±0.15</td>
</tr>
<tr>
<td>β</td>
<td>h⁻¹</td>
<td>0.099±0.017</td>
<td>0.123±0.18</td>
</tr>
<tr>
<td>T1/2a</td>
<td>h</td>
<td>0.315±0.02</td>
<td>0.339±0.044</td>
</tr>
<tr>
<td>T1/2b</td>
<td>h</td>
<td>7.141±1.2</td>
<td>10.159±2.1</td>
</tr>
<tr>
<td>V1</td>
<td>mL</td>
<td>1.681.15±165.13</td>
<td>2.205.59±148.063</td>
</tr>
<tr>
<td>CL</td>
<td>mL/h</td>
<td>1.552.15±105.67</td>
<td>2.246.37±216.859***</td>
</tr>
<tr>
<td>AUC(0–t)</td>
<td>h/μg/mL</td>
<td>2.166±0.086</td>
<td>1.522±0.157***</td>
</tr>
<tr>
<td>AUC(0–∞)</td>
<td>h/μg/mL</td>
<td>3.231±0.226</td>
<td>2.239±0.209**</td>
</tr>
<tr>
<td>K10</td>
<td>h⁻¹</td>
<td>0.929±0.107</td>
<td>1.025±0.162</td>
</tr>
<tr>
<td>K12</td>
<td>h⁻¹</td>
<td>1.262±0.106</td>
<td>1.143±0.242</td>
</tr>
<tr>
<td>K21</td>
<td>h⁻¹</td>
<td>1.82±0.022</td>
<td>1.481±0.192</td>
</tr>
<tr>
<td>MRT(0–t)</td>
<td>h</td>
<td>1.478±0.039</td>
<td>0.808±0.15**</td>
</tr>
<tr>
<td>MRT(0–∞)</td>
<td>h</td>
<td>2.863±0.83</td>
<td>0.812±0.153*</td>
</tr>
</tbody>
</table>

Notes: *Comparison between the two groups, p<0.05. **Comparison between the two groups, p<0.01.

Abbreviations: PL(DOX), doxorubicin-loaded PEGylated liposomes; CPPL(DOX), doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive PEGylated liposomes; T1/2a, elimination half-life; V1, volume of distribution; CL, total clearance; AUC, area under the concentration–time curve; MRT, mean residence time.

The pharmacokinetic parameters are summarized in Table 4. Compared with PL(DOX), the AUC of CPPL(DOX) in tumor and liver increased significantly (p<0.05) but decreased in the spleen; Cmax of CPPL(DOX) increased in tumor and brain but decreased in the heart and spleen. The ratio of AUC in the tumor to blood of CPPL(DOX) was calculated to be 1.84-fold more than that of PL(DOX), indicating CPPL(DOX) are useful for tumor targeting. In addition, the lower distribution in the heart and spleen indicated that CPPL(DOX) had less cardiac toxicity and accelerated blood clearance at the second dosage. PL(DOX) and CPPL(DOX) showed minimal distribution in the lung and brain due to their size and the existence of the BBB. The mechanism that caused the difference in in vivo distribution between PL(DOX) and CPPL(DOX) should be examined in future studies.

Therapy for breast tumors

During the administration period, although there were no animal deaths in any group, the survival status of the CPPL(DOX) group was significantly better than that of the PL(DOX) and NS groups. As shown in the body weight change curve (Figure 4A), the weight of CPPL(DOX) group of nude mice did not decline, but showed an increasing trend, whereas the weight of the nude mice in the PL(DOX) and NS groups decreased with the growth of tumor.

The relative tumor size of each group and the photos of tumors separated from nude mice on the treatment day 9 are shown in Figure 4B and C, respectively. Although the tumor size increased in each group when compared to that measured pretreatment, the tumors in the mice in the CPPL(DOX) and PL(DOX) groups grew more slowly than that in the NS group.

From the antitumor efficacy evaluation index (Figure 4D), the tumor inhibition by CPPL(DOX) was found to be significantly greater than that by PL(DOX), indicating that CPPL(DOX) is a better choice for breast cancer therapy. The results showed that although PL(DOX) accumulated in tumor tissues due to the EPR effect and the existence of the BBB. The mechanism that caused the difference in in vivo distribution between PL(DOX) and CPPL(DOX) should be examined in future studies.
Figure 3 The bio-distribution of PL(DOX) and CPPL(DOX) in nude mice bearing breast tumor (n=3).
Abbreviations: PL(DOX), doxorubicin-loaded PEGylated liposomes; CPPL(DOX), doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive PEGylated liposomes.
Table 4 The pharmacokinetic parameters of PL(DOX) and CPPL(DOX) in tissue (n=3)

<table>
<thead>
<tr>
<th>Tissue</th>
<th>AUC(0–t) (h·µg/g) PL(DOX)</th>
<th>AUC(0–∞) (h·µg/g) PL(DOX)</th>
<th>T_max (h) PL(DOX)</th>
<th>C_max (µg/g) PL(DOX)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor</td>
<td>5.775±0.636</td>
<td>7.475±0.805*</td>
<td>2</td>
<td>1.116</td>
</tr>
<tr>
<td></td>
<td>CPPL(DOX)</td>
<td>7.619±1.765</td>
<td>2</td>
<td>1.600</td>
</tr>
<tr>
<td>Heart</td>
<td>1.490±0.523</td>
<td>0.850±0.229</td>
<td>2</td>
<td>0.398</td>
</tr>
<tr>
<td></td>
<td>CPPL(DOX)</td>
<td>1.901±0.561</td>
<td>2</td>
<td>0.202</td>
</tr>
<tr>
<td>Liver</td>
<td>3.823±0.350</td>
<td>6.017±0.769*</td>
<td>2</td>
<td>0.910</td>
</tr>
<tr>
<td></td>
<td>CPPL(DOX)</td>
<td>5.738±0.793</td>
<td>2</td>
<td>1.365</td>
</tr>
<tr>
<td>Spleen</td>
<td>7.492±0.440</td>
<td>4.405±0.1016*</td>
<td>2</td>
<td>1.390</td>
</tr>
<tr>
<td></td>
<td>CPPL(DOX)</td>
<td>11.017±0.756</td>
<td>2</td>
<td>0.850</td>
</tr>
<tr>
<td>Lung</td>
<td>0.812±0.300</td>
<td>0.676±0.322</td>
<td>2</td>
<td>0.180</td>
</tr>
<tr>
<td></td>
<td>CPPL(DOX)</td>
<td>1.679±0.873</td>
<td>2</td>
<td>0.181</td>
</tr>
<tr>
<td>Kidney</td>
<td>3.530±0.474</td>
<td>4.852±0.467*</td>
<td>4</td>
<td>0.607</td>
</tr>
<tr>
<td></td>
<td>CPPL(DOX)</td>
<td>11.845±6.423</td>
<td>4</td>
<td>0.830</td>
</tr>
<tr>
<td>Brain</td>
<td>0.108±0.0434</td>
<td>0.160±0.0162</td>
<td>2</td>
<td>0.0198</td>
</tr>
<tr>
<td></td>
<td>CPPL(DOX)</td>
<td>0.155±0.0356</td>
<td>2</td>
<td>0.0571</td>
</tr>
</tbody>
</table>

Note: *p<0.05, PL(DOX) served as control.
Abbreviations: PL(DOX), doxorubicin-loaded PEGylated liposomes; CPPL(DOX), doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive PEGylated liposomes; AUC, area under the concentration–time curve; T_max, time at the maximum concentration; C_max, maximum concentration in tissue.

CPP exposure that promotes penetration and endocytosis. According to these criteria, CPPL(DOX) have achieved the therapeutic goal for treating breast tumors. Successful CPPL synthesis may provide more opportunities for the development of therapies for other tumors, including brain gliomas, by combining the positive characteristics of CPPL and receptors expressed on the BBB.

H&E and TUNEL staining
Tumors were separated from the euthanized animals at 48 h after the last administration and stained with H&E. As shown in Figure 5, the tissue structure of the tumor in the NS treatment group was complete and clear with bright-stained nuclei, indicating that cells were in the vigorous growth period. After treatment with PL(DOX), the cells

![Figure 4](image-url)

**Figure 4** (A) Body weight curve. **p<0.01, PL(DOX) as control group. (B) Relative tumor size curve. (C) Photos of tumor on the 9th day after first administration. (D) The relative tumor growth ratio (T/C%). Data are presented as the mean ± SD per group measured at indicated days after treatment (n=6). The arrows indicate the time of administration.

Abbreviations: PL(DOX), doxorubicin-loaded PEGylated liposomes; SD, standard deviation; NS, normal saline; CPPL(DOX), doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive PEGylated liposomes.
had shrunk, which caused a large gap between tissues. Particularly, large areas of exfoliative cells and tissue necrosis appeared in the CPPL(DOX) group, indicating tumor cells were in severe apoptosis. To analyze DNA strand breaks, the TUNEL assay was extensively employed in the assessment of tumor cell apoptosis. As seen in Figure 5, NS did not significantly induce cell apoptosis as demonstrated by the absence of detectable TUNEL-positive tumor cells (green). In contrast, exposure to CPPL(DOX) induced significant apoptosis in cells compared to PL(DOX). The observed trend for apoptosis was consistent with the results in vivo antitumor efficacy.

Overall, these results strongly support our hypothesis that the combination of pH responsiveness and CPP penetration by multifunctional liposomes should enhance MCF-7 cell recognition and uptake and reduce nonspecific uptake. pH-responsive acid cleavage appears to enhance specific cellular uptake through CPP by selectively unmasking PEG in tumor tissues. Subsequently, DOX could escape from endosomes into the nucleus to disrupt DNA synthesis.

**Biocompatibility of CPPL(DOX)**

DOX is widely used in clinical therapy for acute and chronic leukemia, malignant lymphomas, breast, ovarian, and non-small-cell lung cancers, and sarcomas. The most adverse effects of DOX for clinical application are bone marrow suppression and cardiotoxicity. After liposomal encapsulation, the pharmacokinetics of DOX changed and cardiotoxicity was reduced. Although the encapsulation efficiency of DOX in liposomes was >95%, the therapeutic efficacy did not dramatically increase, thereby indicating the need for further improvement of its formulation. In this study, we constructed novel CPPL and evaluated CPPL(DOX) biocompatibility by histological examination and bone marrow suppression after four rounds of administration to healthy mice. PL(DOX) and DOX served as negative and positive controls, respectively. H&E staining (Figure 6A) revealed that tissue sections from different organs did not show any necrosis, inflammation, or enlargement of nuclei in either CPPL(DOX) or PL(DOX) groups, but showed serious signs of necrosis or extravasation of RBCs in the DOX group. Since bio-distribution studies demonstrated higher accumulation of liposomes in the liver and spleen, these organs were carefully examined for any histological changes. In the CPPL(DOX) group, no ballooning of hepatocytes or signs of inflammation was observed in the liver sections, and no signs of necrosis were evident in the tissue sections obtained from the spleen, indicating normal organs and tissues.
Figure 6 (A) H&E staining of organs of interest and (B) the myelosuppressive effect after treatment with three formulations, **\(p<0.01\), DOX served as control.

Abbreviations: H&E, hematoxylin and eosin; DOX, doxorubicin; PL(DOX), doxorubicin-loaded PEGylated liposomes; CPPL(DOX), doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive PEGylated liposomes; BMC, bone marrow cell.

The myelosuppressive effect (Figure 6B) showed that the number of BMCs in the CPPL(DOX) administration group was similar to that in the PL(DOX) group and significantly increased when compared with DOX \((p<0.01)\), indicating CPPL(DOX) was safe even in the liposomes modified with CPP, a non-cell-selective peptide with positive charges.

Conclusion
DOX-encapsulated CPPL, obtained via post-reaction method, exhibited a high encapsulation efficiency of about 90%, leakage stability in serum, and minimal hemolysis, and thus found to be safe for tumor treatment. In in vivo evaluations, CPPL(DOX) demonstrated longer blood circulation, high tumor accumulation, and good biocompatibility in addition to more cell apoptosis induced by DNA disruption and lower relative tumor growth ratio. These findings indicated that the goals of delivering DOX by CPPL to tumor cell nucleus and effective treatment of breast cancer were accomplished.

Acknowledgment
This work was supported by the National Natural Science Foundation of China (grant no 81202469).

Disclosure
The authors have no conflicts of interest to disclose in this work.

References
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.